The study is being conducted to evaluation of the Efficacy and Safety of QL1706 Combined with Chemotherapy Induction in Sequential Immunotherapy Consolidation After Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer(LS-SCLC), and Exploration of the Correlation Between Biomarkers (PD-L1, TMB, ctDNA, etc.) Related to QL1706 Treatment and Treatment Efficacy and Prognosis.
QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.
The patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible.
Pathologically confirmed LS-SCLC
Investigator confirmation of at least one measurable lesion, as defined by RECIST v1.1
ECOG performance status of 0 or 1
Known hypersensitivity to QL1706 or any of its excipients
Histologically confirmed non-small cell lung cancer (NSCLC) or mixed tumor containing an NSCLC component.
History of another primary malignancy or previous allogeneic organ transplantation.
Surgery (other than diagnostic biopsy) within 4 weeks before first dose of study drug.
Shanghai Chest Hospital
Lead sponsor